Advisors Asset Management Inc. Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Advisors Asset Management Inc. raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 74.3% during the third quarter, Holdings Channel reports. The institutional investor owned 2,845 shares of the medical research company’s stock after buying an additional 1,213 shares during the period. Advisors Asset Management Inc.’s holdings in IQVIA were worth $674,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of IQV. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in IQVIA during the third quarter worth approximately $6,059,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of IQVIA by 18.3% in the 3rd quarter. PNC Financial Services Group Inc. now owns 50,364 shares of the medical research company’s stock valued at $11,935,000 after buying an additional 7,804 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA in the 3rd quarter valued at $147,683,000. Finally, Prospera Financial Services Inc purchased a new stake in IQVIA in the third quarter valued at $245,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Down 1.4 %

IQVIA stock opened at $201.24 on Wednesday. The stock’s 50 day moving average price is $221.18 and its 200 day moving average price is $226.75. The company has a market cap of $36.53 billion, a PE ratio of 26.41, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on IQV shares. Barclays dropped their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. BTIG Research cut their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Redburn Atlantic initiated coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.